嘉和生物(06998)拟根据购回授权于市场上购回股份

Core Viewpoint - The company plans to repurchase its shares in the open market based on the general authorization granted by shareholders at the annual general meeting scheduled for June 26, 2025 [1] Group 1 - The repurchased shares may be canceled, held in treasury, sold, or transferred as deemed appropriate by the company [1] - The company believes that the share repurchase will be beneficial for its operations [1] - The board of directors is confident that the share repurchase aligns with the overall interests of the company and its shareholders [1]